Corvus Pharmaceuticals, Inc. (CRVS) Cash Flow Statement
Corvus Pharmaceuticals, Inc. (CRVS) generated -$44.5M of operating cash flow over the twelve months to 2026-06-30, spent $698000 on capital expenditure and had free cash flow of -$45.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CRVSCorvus Pharmaceuticals, Inc.Follow CRVS — free
—
Price chart with a free account
- Market cap
- 885.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -27.9 | -46.2 | -41.0 | -37.3 | -34.8 | -36.7 | -27.0 | -23.9 | -25.4 | -32.8 | -44.5 | |
| Capital expenditure | 2.2 | 0.3 | 0.4 | 0.0 | 0.1 | 0.0 | 0.3 | 0.0 | — | 0.2 | -0.7 | |
| Free cash flow | -30.1 | -46.5 | -41.3 | -37.3 | -34.9 | -36.7 | -27.3 | -24.0 | — | -33.0 | -45.2 | |
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Stock-based compensation | 3.8 | 6.2 | 7.1 | 7.3 | 5.7 | 4.2 | 2.7 | 2.1 | 3.0 | 5.3 | — |
USD millions · SEC XBRL
Corvus Pharmaceuticals, Inc. — questions
- What is Corvus Pharmaceuticals, Inc.'s operating cash flow?
- -$44.5M over the twelve months to 2026-06-30.
- How much does Corvus Pharmaceuticals, Inc. spend on capital expenditure?
- $698000 over the twelve months to 2026-06-30.
- What is Corvus Pharmaceuticals, Inc.'s free cash flow?
- -$45.2M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Corvus Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.